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Available anti-malarial tools have over the ten-year period prior to 2012 dramatically reduced the number of fatalities
due to malaria from one million to less than six-hundred and thirty thousand. Although fewer people now die from
malaria, emerging resistance to the first-line anti-malarial drugs, namely artemisinins in combination with quinolines and
arylmethanols, necessitates the urgent development of new anti-malarial drugs to curb the disease. The quinolones are a
promising class of compounds, with some demonstrating potent in vitro activity against the malaria parasite. This review
summarizes the progress made in the development of potential anti-malarial quinolones since 2008. The efficacy of these
compounds against both asexual blood stages and other stages of the malaria parasite, the nature of putative targets,
and a comparison of these properties with anti-malarial drugs currently in clinical use, are discussed.
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Malaria represents a significant global health threat, with
40% of the world’s population being at risk of contract-
ing this disease. During 2012, nearly six-hundred and
thirty thousand people died from the disease [1], with
pregnant women and children under the age of five be-
ing the most vulnerable to infection [2]. By far the
most (around 90%) deaths occur in sub-tropical and
tropical Africa south of the Sahara (representing
564,300 of the total 627,000 deaths reported in 2012)
[1], indicative of the endemic proportions that malaria
has reached in this region.
Malaria arises from the invasion of red blood cells
(RBCs) by a protozoan of the genus, Plasmodium [3].
Five species of the Plasmodium genus, i.e. Plasmodium
falciparum, Plasmodium ovale, Plasmodium vivax,
Plasmodium malariae, and Plasmodium knowlesi cause
human malaria. Of these species, P. falciparum is re-
sponsible for the most severe form of malaria [4]. The
malaria parasite is transmitted to humans following the
bite of an infected female Anopheles mosquito. The
parasite has a complex life cycle, involving the vector
and a vertebrate host. Figure 1 illustrates the malaria* Correspondence: david.nda@nwu.ac.za
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unless otherwise stated.parasite life cycle that progresses through three different
phases, with each phase comprising its own different
stages.
The liver phase (A): following the bite of an infected
Anopheles mosquito, sporozoites (1) (infectious stage)
are introduced into the bloodstream of the victim (host),
from where they migrate to the liver. In the liver, each
sporozoite develops into a tissue schizont (3). In P. ovale
and P. vivax, the sporozoites develop into hypnozoites
(2), the dormant form responsible for the relapse of the
disease, months after the initial infection.
The blood phase (B): when the tissue schizont (3) rup-
tures in the liver, merozoites are released into the blood-
stream, where they invade the RBCs. Within the RBCs,
each merozoite transforms into a trophozoite (6) and
later into a blood schizont (7), which multiplies asexu-
ally, giving rise to 16–32 merozoites (4). When the in-
fected RBCs rupture, merozoites are released into the
bloodstream to further invade more RBCs and hence
continue asexual multiplication. The clinical manifesta-
tions of the disease (e.g. fever and chills) appear during
this phase. Some of these merozoites develop into game-
tocytes (8).
The mosquito phase (C): when a mosquito feeds on an
infected person, it ingests gametocytes with the blood. The
gametocytes undergo asexual reproduction within the mos-
quito’s mid-gut, producing thousands of sporozoites (1),Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Schematic life cycle of malaria parasite. (A) Liver phase, (B) Blood phase, (C) Mosquito phase. The cycle progresses from (A) to (B),
and then to (C).
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quito, from where they are injected into humans during a
blood meal.
Hitherto, chemotherapy has remained the sole option
for malaria treatment [5]. Quinine, an alkaloid present
in the bark of Cinchona trees, was the first effective
treatment for malaria [6]. Once the structure of quinine
had been established by Rabe et al. [7], the syntheses of
quinine analogues became the next focus. This led
to the discovery of the quinoline chloroquine (CQ)
(Figure 1) and related compounds, such as amodiaquine
and piperaquine. Other quinolines bearing a benzylic
hydroxyl group as in the case of quinine were also pre-
pared, the most important of which was mefloquine [8].
CQ turned out to be the most successful drug: it was
cheap, relatively safe and was used for decades, before
the parasite developed resistance to the drug. Structur-
ally quite different drugs, as represented by Fansidar
(a combination of sulphadoxine and pyrimethamine),
have since been introduced, but unfortunately efficacy
has also been impeded by the development of resist-
ance [9].Artemisinin and its derivatives (2, 3–6, Figure 2),
referred to as the ‘artemisinins’, are another class of anti-
malarial drugs that are fast acting and potent against
all resistant strains of the malaria parasite [10]. In
an attempt to protect the artemisinins against the devel-
opment of parasite resistance, the World Health
Organization (WHO) recommended the use of these
drugs in combination with other drugs, rather than in
monotherapy. This led to the adoption of artemisinin
based combination therapy (ACT) for the treatment of
uncomplicated malaria in endemic countries. ACT com-
bines an artemisinin derivative with a longer half-life
anti-malarial drug. The rationale is that the fast acting
artemisinin clears a larger proportion of the parasites
within its short pharmacological half-life, whilst the
longer half-life partner drug then continues the clear-
ance as the artemisinin concentration falls to sub-
therapeutic levels. In spite of this, tolerance to ACTs
by the parasite has been reported in South-East Asia
[11,12], which is indicative of emerging resistance to
the artemisinins. With the recent identification of
genetic markers of the resistant phenotype and the
Figure 2 Structures of chloroquine (1), artemisinin (2) and its derivatives: dihydroartemisinin (3), artemether (4), arteether (5), artesunate (6),
and primaquine (7).
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search for new anti-malarial drugs becomes of utmost
importance [13].
The anti-malarial drugs discussed above are more ef-
fective against the blood stage than any other stage of
the malarial parasite. Primaquine is the only clinically
proven drug that effectively kills hypnozoites (2) (the
liver stage of the P. vivax parasite), and is also active
against gametocytes (8) (the transmission stage of the
parasite). Primaquine, however, causes fatal haemolysis
in patients with glucose-6-phosphate dehydrogenase
deficiency, an adverse side effect that has significantly
limited its use [14].
Overall, resistance and tolerance associated with cur-
rently available anti-malarial drugs have created a driv-
ing force to the search for new chemical entities having
novel modes of action, being readily available and meet-
ing the Medicines for Malaria Venture (MMV) require-
ments for the next generation drugs needed to eradicate
malaria. According to MMV, a suitable drug candidate for
malaria eradication should be able to kill gametocytes,
hypnozoites and other liver stages, thereby inhibiting
transmission, relapse, as well as providing prophylaxis
against the disease. Ideally, such a potential candidate
should also have a minimum half-life of three days [15],
although in practice such a property may be difficult to
achieve.Figure 3 The quinolone scaffold.Review
One way of uncovering new compounds involves evalu-
ating highly efficacious compounds in other therapeutic
fields. It is apparent that some of these compounds con-
tain the quinolone scaffold and are active against the
malaria parasite.The quinolone scaffold
Quinolones are synthetic compounds containing the 4-
oxo-1,4-dihydroquinoline skeleton that may be written
as the tautomeric 4-hydroxyquinoline (Figure 3). They
are mostly used as antibiotics [16]. The first anti-bacterial
quinolone, nalidixic acid, was discovered as a by-product
during the synthesis of CQ [17]. Since the discovery of
nalidixic acid and its anti-bacterial properties against gram
negative bacteria, several structural modifications have
been made to widen its spectrum of activity to also in-
clude gram positive bacteria [18].
Besides possessing bactericidal properties, the quin-
olone scaffold is present in the structures of certain
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in anti-oxidants [21]. The scaffold is also incorpo-
rated into compounds that display anti-malarial ac-
tivity [22].
Reports on the anti-malarial properties of quino-
lones, compared to their anti-bacterial properties, are
relatively limited. Recent research involving the evalu-
ation of anti-malarial properties of quinolones, how-
ever, indicates that these compounds demonstrate
promising potential. They show very good efficacies
and target more than one stage of the malaria parasite
life cycle, including the blood, liver and gametocyte
stages. They also seem to have novel modes of action,
different from those of most of the current, clinically
used drugs. Thus, in this review are presented details
of anti-malarial quinolones documented within the
past six years.Quinolones
Endochin and its analogues
The anti-malarial properties of endochin (8, Figure 4)
have been known since 1948, when its activity against
avian malaria was demonstrated [23]. Further research
on this molecule has established that it is active against
both the liver (phase A, Figure 1) and blood (phase B,
Figure 1) stages of the parasites. It targets the cyto-
chrome bc1 complex of the parasite [22]. However,
endochin has proven to be ineffective in vivo against
human malaria [24]. Its failure in humans has been as-
cribed to the fact that endochin is easily metabolized
to inactive metabolites in the presence of cytochrome
P450 (CYP450) enzymes [25].Figure 4 Structures of endochin and its derivatives.Recent advances in understanding of both the drug
mechanism of action and the manner in which resist-
ance may arise suggest that previously abandoned lead
molecules may in fact be viable anti-malarial drug candi-
dates. This awareness has led to both a re-examination
of many abandoned molecules, including quinolone
endochin, and the activation of synthetic campaigns,
aimed at generating more robust and potent analogues.
These activities are exemplified by the development of
the following new endochin analogues that have im-
proved therapeutic properties, compared to the parent
endochin.
2-Methyl-3-(n-heptyl)-5,7-difluoroquinolone (ELQ-121)
Replacement of the methoxyl group at C-7 by fluorine
and the insertion of fluorine at C-5 result in the com-
pound, ELQ-121 (9, Figure 4). It has a half-maximal
inhibitory concentration (IC50) value of 0.1 nM against
the CQ sensitive (D6) and CQ resistant (Dd2) strains of
P. falciparum. It is stable in the presence of microsomal
elements (CYP450). The parent endochin has an IC50
value of 4 nM against the D6 and Dd2 strains and is
unstable in the presence of CYP450 enzymes [25]. Thus,
relative to endochin, the derivative ELQ-121 shows an
approximate forty-fold improvement in IC50 for the
inhibition of P. falciparum in vitro and exhibits an en-
hanced metabolic stability.
2-Methyl-3-(n-heptyl)-6-cloroquinolone (ELQ-130)
Insertion of chlorine at C-6 results in the compound,
ELQ-130 (10, Figure 4). It has an IC50 value of 16 nM
against the TM90-C2B strain of P. falciparum. Although
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(IC50 value of 11 nM against the same strain), ELQ-130
has enhanced metabolic stability than endochin and is
devoid of cross-resistance with atovaquone [25].
4-(2,5,8,11-Tetraoxatridecan-13-yl-carbonate)-2-methyl-3-(n-
heptyl)-5,7-difluorquinolone (ELQ-125)
ELQ-125 (11, Figure 4) is a polyethylene glycol (PEG)
conjugate of ELQ-121. It has, in addition to the two
fluorine atoms at positions 5 and 7, a PEG moiety linked
to the oxygen of the quinolone nucleus. It has an IC50
value of 0.4 nM against the D6 and Dd2 strains and is
hence ten-fold (0.4 nM vs 4 nM) more active than the
parent endochin. ELQ-125 displays higher oral bio-
availability than both ELQ-121 and endochin. This prop-
erty is attributed to the presence of the PEG moiety,
which also enhances the aqueous solubility of the com-
pound. As such, ELQ-125 does not have the solubility
problem of endochin and its other analogues. ELQ-125
completely removed parasites from the blood stream of
mice infected with Plasmodium yoelii on the third day
of treatment, at a dose of 50 mg/kg/day, whereas endo-
chin showed no activity in infected mice [25].
3-Phenyl-4(1H)-quinolone
This analogue (12, Figure 4) has the n-heptyl chain at
C-3 of endochin replaced by a phenyl ring, whilst a
chlorine atom replaces the H atom at C-6. These modi-
fications confer better aqueous solubility and micro-
somal stability relative to the parent endochin. This
compound has an EC50 value of 15.3 nM against the
TM90-C2B strain of P. falciparum in vitro. Compound
12 is therefore more potent than endochin, with an
EC50 value of 46.6 nM against the same strain. It is im-
portant to note that this analogue shows no cross-
resistance with atovaquone, contrary to endochin [26].
More importantly, results from in vivo studies indicated
that the compound completely prevented exflagellation of
microgametocytes at a dose of 10 μM, administered for
fourteen days post infection. As such, this analogue has




In P4Q-158 (13, Figure 4), the n-heptyl chain of endo-
chin is replaced with a trifluorotoluene moiety at C-3,
whereas a chlorine atom replaces the H atom at C-6.
P4Q-158 has potent anti-malarial activity in vitro, with
an IC50 value of 3.07 nM against the liver stage of the
Plasmodium berghei parasite. However, its potency is
slightly less than that of atovaquone that has an IC50
value of 1.42 nM against the liver stage of P. berghei.
P4Q-158 also demonstrates strong activity against theliver stage of P. berghei in vivo, as mice treated with this
compound at a dose of 10 mg/kg displayed a more than
60% survival rate, compared to untreated mice [28].
6-Chloro-7-methoxy-2-methyl-3-{4-[4-(trifluoromethyl)
phenoxy]phenyl}quinolin-4(1H)-one (ELQ-300)
ELQ-300 (14, Figure 4) has a diaryl ether moiety re-
placing the C-3 n-heptyl substituent of endochin. Be-
sides being metabolically more stable than endochin,
ELQ-300 exhibits potent ex vivo anti-malarial activity
against MDR P. falciparum, having IC50 values of 1.8
nM and 1.7 nM against the W2 and TM90-C2B strains,
respectively. The drug is thus substantially more potent
than CQ that has IC50 values of 126 nM and 96.2 nM
against the W2 and TM90-C2B strains respectively.
Furthermore, ELQ-300 shows no cross-resistance with
atovaquone, displays a high selectivity for the parasite
respiratory bc1 complex (selectivity index ≥ 20,000), and
is very potent against the early and late stages of P.
falciparum gametocytes. At a concentration of 0.1 μM,
ELQ-300 completely stopped further development of
stage I and II gametocytes, and it is active against stage
IV gametocytes, with an IC50 value of 79.1 nM. It also
has an ED50 value of 0.02 mg/kg/day against murine P.
yoelii. At a dose of 0.3 mg/kg/day, administered for
30 days post infection, ELQ-300 completely cleared
parasites in infected murine models [29]. Presently,
ELQ-300 is undergoing formulation studies in preparation
for clinical studies [30].
Hydroxy-2-dodecyl-4-(1H)-quinolone (HDQ) and its
analogues
HDQ (15, Figure 5) is the only compound known to in-
hibit both the NADH:ubiquinone oxidoreductase en-
zyme (PfNHD-2) and the bc1 complex in the respiratory
chain of P. falciparum. This multi-target inhibition con-
fers a benefit over the single target inhibition in that the
former delays the onset of drug resistance [31]. Because
of this advantage, HDQ had been used as a starting
point for a drug discovery project that has led to several
new quinolone analogues with promising anti-malarial
activities. Examples of the most effective of these ana-
logues are discussed next.
7-Chloro-3-methyl-2-{4-[4-(trifluoromethoxy)benzyl]phenyl}
quinolin-4(1H)-one (CK-2-68)
This HDQ derivative (16, Figure 5) bears a [4-(4-
trifluoromethoxy)benzyl]phenyl group at C-2 of the
quinolone nucleus instead of the metabolically vulnerable
n-dodecyl unit present in HDQ. This 2-bisaryl quinolone
has an IC50 of 31 nM against the 3D7 strain of P. falcip-
arum in vitro. When given orally at a concentration of
20 mg/kg, CK-2-68 completely cleared P. berghei parasites
in mice. It is stable in the presence of human
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oxidoreductase of P. falciparum with an IC50 value of
16 nM. This compares to a value higher than 1,000 nM
for atovaquone. CK-2-68 and its phosphate pro-drug
(17, Figure 5) have activities against P. falciparum
microgametocytes similar to that of atovaquone
(IC50 ~ 10 μM) [31-33].
7-Fluoro-3-methyl-2-{6-[4-(trifluoromethoxy)phenyl]pyridin-
3-yl}quinolin-4(1H)-one (SL-2-64)
In SL-2-64 (18, Figure 5), a 2-[(4-trifluoromethoxy)ben-
zyl)]pyridine moiety replaces the n-dodecyl unit at C-2
in HDQ. The pyridine unit in this molecule lowers
lipophilicity and increases aqueous solubility relative to
CK-2-68. SL-2-64 has activity comparable to that of
some clinically used anti-malarial drugs against the 3D7
strain of P. falciparum. In vivo, this derivative has an
ED50 value of 3.3 mg/kg against the 3D7 strain in mur-
ine models. This activity is similar to that of artemether,
which has an ED50 value of 3.1 mg/kg against the same
strain. This HDQ analogue is listed in the MMV discov-
ery pipeline [31].
Acridinones
Acridinones are tricyclic compounds incorporating the 4-
oxo-1,4-dihydroquinolone skeleton, and are thus structur-
ally closely related to quinolones. The anti-malarial activity
of a compound containing the acridinone scaffold (19,
Figure 6) was reported in 1947 [34]. This compound gar-
nered little interest until 1970 when the anti-malarial
prophylactic property of floxacrine came (an analogue
of acridinone) was discovered [35]. Shortly after floxa-
crine came, WR 243251 (20, Figure 6) with improved
therapeutic properties. However, these compounds were
not further evaluated, due to their poor aqueous solubility
and metabolic instability [36]. Recent studies aimed at re-
evaluating the acridinone scaffold through structure–
property relationships (SPR) and optimization by using
structure-activity relationships (SAR) have led to the dis-
covery of promising anti-malarial analogues.Figure 5 Structure of HDQ and its derivatives.6-{4-[4-(Trifluoromethyl)phenoxy]phenyl}-1,3,4,4a,9a,10-
hexahydroacridin-9(2H)-one (THA 118)
THA 118 (21, Figure 6) has a diphenyl ether moiety re-
placing the phenyl moiety at C-6 in WR 243251. THA
118 possesses more potent anti-malarial activity and
has improved metabolic stability and solubility relative
to WR 243251. Indeed, THA 118 displays anti-malarial
activity in vitro with EC50 values of 12.2 nM and 9.1 nM
against the W2 and TM90-C2B strains of P. falciparum
respectively, compared to WR 243251, which has EC50




This analogue (22, Figure 6) possesses potent in vitro
anti-malarial activity (IC50 15 nM) comparable to that of
CQ (IC50 7.4 nM) against the D6 strain of P. falciparum
[38]. WR 249685 has a higher selectivity index for the para-
site bc1 complex than does atovaquone. This was estab-
lished by comparing their in vitro therapeutic indices
(IVTI) for the human bc1 complex, i.e. IVTI was 4,600 for
WR 249685 and 24 for atovaquone. In addition to targeting
the parasite bc1 complex, WR 249685 also binds to haem,
although it has a low affinity for haem compared to CQ
[39]. Thus, it is unlikely to exert an anti-malarial effect in
this manner relative to CQ.
Haloalkoxyacridinones
This is a relatively new class of acridinone [38]. The
most active analogues in this class have at C-3 of the
acridone ring an alkoxy moiety terminating in one or
more trifluoromethyl units. The acridinone (23, Figure 6)
is an example of such an analogue. It exhibits extraor-
dinarily strong anti-malarial activity in vitro, with IC50
values of 1 pM against both the D6 and Dd2 strains of
P. falciparum. With such favourable IC50 values, this
compound appears to be the most effective anti-malarial
ever synthesized and tested in a laboratory. Although its
mode of action is still unknown, it is assumed that it
Figure 6 Structure of acridinone and analogues.
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with known anti-malarial drugs targeting that complex.
This acridinone analogue has an in vitro therapeutic
index higher than 100,000 [39] and has been patented in
the US as an anti-malarial drug [40].
3-Chloro-6-(2-diethylamino-ethoxy)-10-(2-diethylamino-
ethyl)-acridinone (T3.5)
This 10-N substituted acridinone analogue (24, Figure 6)
incorporates two potential anti-malarial features, namely,
a haem-targeting unit through the tricyclic acridone
core, and a quinoline resistance-reversal unit, due to the
N-(2-diethylamino-ethyl) unit. T3.5 has in vitro IC50
values of 77.3 nM and 71.3 nM against the Dd2 and
TM90-C2B strains of P. falciparum, respectively. In
comparison, CQ has IC50 values of 124.7 nM and 122.7
nM against the same strains respectively. This acridi-
none analogue is non-toxic to mammalian cell lines
both in vitro and in vivo and exhibits synergism with
each of piperaquine, CQ and amodiaquine against the
Dd2 strain [41].
Carboxyquinolones
Since the discovery of the anti-malarial activity of ICI56-
780 (25, Figure 7) [42], recent research on quinolone
anti-malarial drugs has focused on carboxyl derivatives
of quinolones. Due to the need for cheap anti-malarialFigure 7 Structures of carboxylquinolones.drugs that have novel modes of action, commercially
available compounds with antiparasitic activity had been
screened for anti-malarial activity. This has led to the
discovery of various 3-carboxylquinolones as potential
anti-malarial drugs.Ethyl 2-(1,3-benzodioxol-5-yl)-7-methoxy-4-oxo-1,4-
dihydroquinoline-3-carboxylate (TDR 42098)
This compound demonstrates improved potency against
the blood stages of the CQ-R K1 and CQ-S NF54 strains
of P. falciparum, and has better physicochemical proper-
ties, than endochin analogues, bearing a lipophilic side
chain [43]. Derivatization of TDR 42098 (26, Figure 6) pro-
duced the analogue (27, Figure 7) bearing a meta-
substituted aromatic ring at C-2. This derivative has mid-
range EC50 values of 0.13 μM and 0.10 μM against the K1
and 3D7 strains of P. falciparum, respectively [44].6-Deoxy-7-ethoxy-4-oxo-1H-quinoline-3-carboxylic acid
ethyl ester (decoquinate (DQ))
The anti-malarial activities of this long used anti-
coccidial drug were recently discovered during screening
conducted against the liver stages of P. falciparum. In
vitro, decoquinate (DQ) (28, Figure 7) is potent against
the liver (IC50 2.6 nM), blood (IC50 10 nM), and sexual
(IC50 36 nM) stages of the malaria parasite. It reportedly
Figure 8 All structures, and their potencies.
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cross-resistance with atovaquone [45,46].
According to the results of the above studies, it is ap-
parent that DQ meets the MMV requirements for the
next generation drugs needed for malaria eradication
[15]. Despite demonstrating good anti-malarial activity,
DQ has the major liability of poor aqueous solubility. It
also undergoes facile metabolism to the free carboxylic
acid. However, DQ is a very cheap compound and is
readily available. Thus, it is apparent that new deriva-
tives of DQ can be prepared through reducing the lipo-
philicity, enhancing both the solubility and metabolic
stability by replacing the ester group by appropriate
amide groups.
The important features of each compound are summa-
rized in Figure 8.
Conclusion
The quinolone nucleus is a chemotype common to classes
of chemotherapeutic agents including antibiotic, anti-viral
and anti-cancer drugs. More recent research on the anti-
malarial activities of quinolones indicates that such com-
pounds are relatively potent against the blood, liver and
transmission stages of the malarial parasite and act on one
or more targets of the parasite. These findings overall
indicate the importance of the quinolone nucleus in the
development of drugs aimed at eradicating malaria. Never-
theless, more research is required in order to address the
specific difficulties associated with quinolone lead com-
pounds, including those of relatively poor aqueous solubil-
ity and metabolic instability.
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